<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptor γ (PPARγ) may serve as a useful target for drug development in non-diabetic diseases </plain></SENT>
<SENT sid="1" pm="."><plain>However, some <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells are resistant to PPARγ <z:chebi fb="4" ids="48705">agonists</z:chebi> by mechanisms that are poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we provide the first evidence that elevated PPARδ expression and/or activation of PPARδ antagonize the ability of PPARγ to induce colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>More importantly, the opposing effects of PPARδ and PPARγ in regulating programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> are mediated by survivin and caspase-3 </plain></SENT>
<SENT sid="4" pm="."><plain>We found that activation of PPARγ results in decreased survivin expression and increased caspase-3 activity, whereas activation of PPARδ counteracts these effects </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings suggest that PPARδ and PPARγ coordinately regulate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell fate by controlling the balance between the cell <z:hpo ids='HP_0011420'>death</z:hpo> and survival and demonstrate that inhibition of PPARδ can reprogram PPARγ ligand-resistant cells to respond to PPARγ <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
</text></document>